An Emerging Role for Sigma Receptor 1 in Personalized Treatment of Breast Cancer
Despite the major progress in treating breast cancer, recurrence remains a problem and types such as triple-negative breast cancer still lack targeted medicine. The orphan Sigma receptor1 (SigmaR1) has emerged as a target in breast cancer, but its mechanism of action is unclear and hinders clinical...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/13/3464 |
| _version_ | 1797591958091202560 |
|---|---|
| author | Taylor S. Robinson Mahasin A. Osman |
| author_facet | Taylor S. Robinson Mahasin A. Osman |
| author_sort | Taylor S. Robinson |
| collection | DOAJ |
| description | Despite the major progress in treating breast cancer, recurrence remains a problem and types such as triple-negative breast cancer still lack targeted medicine. The orphan Sigma receptor1 (SigmaR1) has emerged as a target in breast cancer, but its mechanism of action is unclear and hinders clinical utility. SigmaR1 is widely expressed in organ tissues and localized to various sub-cellular compartments, particularly the endoplasmic reticulum (ER), the mitochondrial-associated membranes (MAMs) and the nuclear envelope. As such, it involves diverse cellular functions, including protein quality control/ER stress, calcium signaling, cholesterol homeostasis, mitochondrial integrity and energy metabolism. Consequently, SigmaR1 has been implicated in a number of cancers and degenerative diseases and thus has been intensively pursued as a therapeutic target. Because SigmaR1 binds a number of structurally unrelated ligands, it presents an excellent context-dependent therapeutic target. Here, we review its role in breast cancer and the current therapies that have been considered based on its known functions. As SigmaR1 is not classified as an oncoprotein, we propose a model in which it serves as an oligomerization adaptor in key cellular pathways, which may help illuminate its association with variable diseases and pave the way for clinical utility in personalized medicine. |
| first_indexed | 2024-03-11T01:45:00Z |
| format | Article |
| id | doaj.art-3c8a49949a3d4a52be2cacc98d97c3ee |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T01:45:00Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-3c8a49949a3d4a52be2cacc98d97c3ee2023-11-18T16:17:22ZengMDPI AGCancers2072-66942023-07-011513346410.3390/cancers15133464An Emerging Role for Sigma Receptor 1 in Personalized Treatment of Breast CancerTaylor S. Robinson0Mahasin A. Osman1Department of Medicine, Division of Oncology, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43614, USADepartment of Medicine, Division of Oncology, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43614, USADespite the major progress in treating breast cancer, recurrence remains a problem and types such as triple-negative breast cancer still lack targeted medicine. The orphan Sigma receptor1 (SigmaR1) has emerged as a target in breast cancer, but its mechanism of action is unclear and hinders clinical utility. SigmaR1 is widely expressed in organ tissues and localized to various sub-cellular compartments, particularly the endoplasmic reticulum (ER), the mitochondrial-associated membranes (MAMs) and the nuclear envelope. As such, it involves diverse cellular functions, including protein quality control/ER stress, calcium signaling, cholesterol homeostasis, mitochondrial integrity and energy metabolism. Consequently, SigmaR1 has been implicated in a number of cancers and degenerative diseases and thus has been intensively pursued as a therapeutic target. Because SigmaR1 binds a number of structurally unrelated ligands, it presents an excellent context-dependent therapeutic target. Here, we review its role in breast cancer and the current therapies that have been considered based on its known functions. As SigmaR1 is not classified as an oncoprotein, we propose a model in which it serves as an oligomerization adaptor in key cellular pathways, which may help illuminate its association with variable diseases and pave the way for clinical utility in personalized medicine.https://www.mdpi.com/2072-6694/15/13/3464breast cancer biomarkersigma receptor1breast canceroligomerizationIQGAP1Cdc42 |
| spellingShingle | Taylor S. Robinson Mahasin A. Osman An Emerging Role for Sigma Receptor 1 in Personalized Treatment of Breast Cancer Cancers breast cancer biomarker sigma receptor1 breast cancer oligomerization IQGAP1 Cdc42 |
| title | An Emerging Role for Sigma Receptor 1 in Personalized Treatment of Breast Cancer |
| title_full | An Emerging Role for Sigma Receptor 1 in Personalized Treatment of Breast Cancer |
| title_fullStr | An Emerging Role for Sigma Receptor 1 in Personalized Treatment of Breast Cancer |
| title_full_unstemmed | An Emerging Role for Sigma Receptor 1 in Personalized Treatment of Breast Cancer |
| title_short | An Emerging Role for Sigma Receptor 1 in Personalized Treatment of Breast Cancer |
| title_sort | emerging role for sigma receptor 1 in personalized treatment of breast cancer |
| topic | breast cancer biomarker sigma receptor1 breast cancer oligomerization IQGAP1 Cdc42 |
| url | https://www.mdpi.com/2072-6694/15/13/3464 |
| work_keys_str_mv | AT taylorsrobinson anemergingroleforsigmareceptor1inpersonalizedtreatmentofbreastcancer AT mahasinaosman anemergingroleforsigmareceptor1inpersonalizedtreatmentofbreastcancer AT taylorsrobinson emergingroleforsigmareceptor1inpersonalizedtreatmentofbreastcancer AT mahasinaosman emergingroleforsigmareceptor1inpersonalizedtreatmentofbreastcancer |